RxDoctor Payments DataLook up a doctor →

Kathleen Mullin

Neurology · Stamford, CTNPI 1740428317

Payments from drug & device makers

$1,104,389in general payments, 2019–2025

Across 1,655 payments — averaging $667.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$436K
  • H. Lundbeck A S$247K
  • Biohaven Pharmaceutical Holding Company Ltd.$132K
  • Pfizer$102K
  • Lilly USA, LLC$89K
  • AbbVie$32K
  • plus $66K from 54 others
$59,971in research payments, 2019–2025

Across 22 payments — averaging $2725.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$60K

What the payments were for

  • Consulting fees$63,37527%
  • Speaking & faculty fees$135,47957%
  • Grants$850%
  • Travel & lodging$11,3615%
  • Food & beverage$26,87911%
  • Education$1590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biohaven Pharmaceuticals, Inc.66$436,035
H. Lundbeck A S30$246,783
Biohaven Pharmaceutical Holding Company Ltd.41$132,358
Pfizer89$101,980
Lilly USA, LLC204$88,756
AbbVie(2 entities)349$31,968
Amgen(2 entities)85$19,941
Teva Pharmaceuticals USA, Inc.76$18,633
Whitehall International Inc1$6,000
Axsome Therapeutics, Inc.11$5,211
Lundbeck LLC26$2,267
Eli Lilly10$2,222
Amneal Pharmaceuticals LLC76$1,113
CSL Behring66$983
Neurelis, Inc.22$756
Bristol Myers Squibb40$593
Novartis45$572
Neurocrine Biosciences, Inc.20$522
Avanir Pharmaceuticals, Inc.26$512
UCB, Inc.19$458
Harmony Biosciences LLC22$409
Argenx US, Inc.21$403
Eisai Inc.16$370
Genentech USA, Inc.16$355
EMD Serono, Inc.14$337
Impel Pharmaceuticals Inc.18$335
Takeda Pharmaceuticals U.S.A., Inc.17$320
Sanofi18$309
Scilex Pharmaceuticals Inc.18$260
Ipsen Biopharmaceuticals, Inc10$217
Bausch Health US, LLC11$202
ANI Pharmaceuticals, Inc.6$168
Grifols USA, LLC8$166
Assertio Therapeutics, Inc.12$150
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$135
Alnylam Pharmaceuticals Inc.6$134
Mallinckrodt Hospital Products Inc.6$130
Upsher-smith Laboratories LLC6$127
Johnson & Johnson5$123
Jazz Pharmaceuticals Inc.6$121
Acorda Therapeutics, Inc7$116
Kyowa Kirin, Inc.6$113
Ironshore Pharmaceuticals Inc.5$109
Biogen6$108
Idorsia Pharmaceuticals US Inc5$105
Sunovion Pharmaceuticals Inc.7$100
Promius Pharma LLC6$93
SK Life Science, Inc.4$90
Impel Pharmaceuticals LLC4$78
Zyla Life Sciences, Inc.5$77
Supernus Pharmaceuticals, Inc.4$76
Merz North America, Inc.5$68
Arbor Pharmaceuticals, Inc.4$65
Merck3$61
MDD US Operations, LLC2$53
Sumitomo Pharma America, Inc.5$53
Otsuka America Pharmaceutical, Inc.2$48
Catalyst Pharmaceuticals, Inc.2$47
Currax Pharmaceuticals LLC3$44
E.r. Squibb & Sons, L.L.C.3$43

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,104,389 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate14$27,734
Emgality PenGalcanezumab-Gnlm17$11,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$101,980$27,73414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 neurology providers in Connecticut.

Other neurology in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →